Get the Stockscreener App
5.39
0.19%
0.010
After Hours:
5.39
Curevac N V stock is traded at $5.39, with a volume of 383.94K.
It is up +0.19% in the last 24 hours and up +0.94% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.38
Open:
$5.37
24h Volume:
383.94K
Relative Volume:
0.65
Market Cap:
$1.21B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.8286
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-0.37%
1M Performance:
+0.94%
6M Performance:
+68.97%
1Y Performance:
+85.22%
1-Day Range:
$5.36
$5.40
1-Week Range:
$5.35
$5.44
52-Week Range:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.39 | 1.21B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
Will CureVac N.V. stock benefit from green energy trendsTrade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
Is CureVac N.V. trending in predictive chart models2025 Buyback Activity & Expert Approved Trade Ideas - newser.com
Can trapped investors hope for a rebound in CureVac N.V.2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - newser.com
How to build a dashboard for CureVac N.V. stock2025 Performance Recap & Weekly High Momentum Picks - newser.com
Pattern recognition hints at CureVac N.V. upsideJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - newser.com
Reversal indicators forming on CureVac N.V. stockTrade Ideas & Free Verified High Yield Trade Plans - newser.com
Signal strength of CureVac N.V. stock in tech scannersEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
CureVac (NASDAQ:CVAC) Earns "Hold (C-)" Rating from Weiss Ratings - MarketBeat
How institutional ownership impacts CureVac N.V. stockJuly 2025 Trends & Community Consensus Trade Alerts - newser.com
Sector ETF performance correlation with CureVac N.V.2025 Winners & Losers & Safe Swing Trade Setup Alerts - newser.com
Is CureVac N.V. stock reversal real or fake2025 Short Interest & Intraday High Probability Setup Alerts - newser.com
Will CureVac N.V. benefit from macro trendsCEO Change & Long-Term Capital Growth Strategies - newser.com
Real time breakdown of CureVac N.V. stock performanceJuly 2025 Analyst Calls & Real-Time Stock Price Movement Reports - newser.com
Should you hold or exit CureVac N.V. nowTrade Ideas & Growth Focused Entry Reports - newser.com
Technical analysis overview for CureVac N.V. stockJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
Technical signs of recovery in CureVac N.V.Weekly Earnings Recap & Low Drawdown Investment Strategies - newser.com
Can machine learning forecast CureVac N.V. recoveryWeekly Gains Summary & AI Optimized Trade Strategies - newser.com
What MACD and RSI say about CureVac N.V.Weekly Earnings Recap & Expert Approved Trade Ideas - newser.com
CureVac N.V. (NASDAQ:CVAC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
How to manage a losing position in CureVac N.V.Market Movement Recap & Daily Profit Focused Stock Screening - newser.com
Analyzing CureVac N.V. with risk reward ratio charts2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com
CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha
What Wall Street predicts for CureVac N.V. stock priceMarket Performance Report & Capital Protection Trading Alerts - newser.com
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):